4.4 Article

Age-Specific Incidence of Melanoma in the United States

Journal

JAMA DERMATOLOGY
Volume 156, Issue 1, Pages 57-64

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamadermatol.2019.3353

Keywords

-

Categories

Funding

  1. National Institutes of Health [P30CA015704, T32CA009515, T32CA092408, T32CA009168]
  2. Fred Hutchinson Cancer Research Center Integrated Immunotherapy Research Core
  3. Society for Immunotherapy of Cancer-Merck fellowship

Ask authors/readers for more resources

Importance Melanoma is epidemiologically linked to UV exposure, particularly childhood sunburn. Public health campaigns are increasing sun-protective behavior in the United States, but the effect on melanoma incidence is unknown. Objective To examine the incidence of melanoma in the United States and whether any age-specific differences are present. Design, Setting, and Participants Observational, population-based registry data were extracted on July 3, 2018, from the combined National Program of Cancer Registries-Surveillance Epidemiology and End Results United States Cancer Statistics database for 2001-2015. Deidentified data for 988103 cases of invasive melanoma, with International Classification of Diseases for Oncology histologic categorization codes 8720 to 8790, were used for analysis. Data analysis was performed from July 1, 2018, to March 1, 2019. Main Outcomes and Measures The annual rates of melanoma in pediatric, adolescent, young adult, and adult age groups were determined. Analyses were stratified by sex, and incidence rates were age-adjusted to the 2000 US standard population. Annual percentage change (APC) in incidence rate was calculated over the most recent decade for which data were available (2006-2015) using the weighted least squares method. Results In 2015, 83362 cases of invasive melanoma were reported in the United States, including 67 in children younger than 10 years, 251 in adolescents (10-19 years), and 1973 in young adults (20-29 years). Between 2006 and 2015, the overall incidence rate increased from 200.1 to 229.1 cases per million person-years. In adults aged 40 years or older, melanoma rates increased by an APC of 1.8% in both men (95% CI, 1.4%-2.1%) and women (95% CI, 1.4%-2.2%). In contrast, clinically and statistically significant decreases were seen in melanoma incidence for adolescents and young adults. Specifically, incidence rates decreased by an APC of -4.4% for male adolescents (95% CI, -1.7% to -7.0%), -5.4% for female adolescents (95% CI, -3.3% to -7.4%), -3.7% for male young adults (95% CI, -2.5% to -4.8%), and -3.6% for female young adults (95% CI, -2.8% to -4.5%). Data on skin pigmentation and sun protection history were unavailable; similar trends were observed with data limited to non-Hispanic whites. Young adult women appeared to have twice the risk of melanoma as young adult men. Conclusions and Relevance The incidence of invasive melanoma in the United States appeared to decrease in adolescents and young adults from 2006 to 2015, and this finding contrasted with increases in older populations. These incidence trends suggest that public health efforts may be favorably influencing melanoma incidence in the United States. Question Is the incidence of melanoma in the United States changing between age groups? Findings In this population-based study including 988103 cases of invasive melanoma reported between 2001 and 2015, the melanoma incidence increased overall but decreased among individuals aged 10 to 29 years at diagnosis in the United States from 2006 to 2015. These findings were based on data from the US Cancer Statistics National Program of Cancer Registries. Meaning The apparent decline in the incidence of melanoma in adolescents and young adults in the United States contrasts with increased incidence in melanoma in older ages and is possibly associated with sun protective interventions, providing support for ongoing prevention efforts. This population-based study examines the incidence of melanoma in the United States overall as well as in different age cohorts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance

Christopher W. Lewis, Jamiluddin Qazi, Daniel S. Hippe, Kristina Lachance, Hannah Thomas, Maclean M. Cook, Ilsa Juhlin, Neha Singh, Zoe Thuesmunn, Seesha R. Takagishi, Aubriana McEvoy, Coley Doolittle-Amieva, Shailender Bhatia, Kelly G. Paulson, Ryan B. O'Malley, Carolyn L. Wang, Paul Nghiem

CANCER MEDICINE (2020)

Article Dermatology

Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients

Neha Singh, Nora A. Alexander, Kristina Lachance, Christopher W. Lewis, Aubriana McEvoy, Gensuke Akaike, David Byrd, Sanaz Behnia, Shailender Bhatia, Kelly G. Paulson, Paul Nghiem

Summary: Baseline imaging in patients with clinically node-negative Merkel cell carcinoma (MCC) identified occult metastatic disease at a higher rate than reported for melanoma (13.2% vs <1%). These findings suggest that baseline imaging is recommended for patients with clinically node-negative MCC, as it frequently leads to upstaging and significantly impacts management and prognosis.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Review Oncology

Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists

Dario Callegaro, Chandrajit P. Raut, Emily Z. Keung, Teresa Kim, Cecile Le Pechoux, Javier Martin-Broto, Alessandro Gronchi, Carol Swallow, Rebecca Gladdy

Summary: The COVID-19 pandemic has greatly impacted cancer patients' access to surgery, but surgical oncologists can adapt their decision-making by revisiting treatment options.

JOURNAL OF SURGICAL ONCOLOGY (2021)

Review Biotechnology & Applied Microbiology

Key chemokines direct migration of immune cells in solid tumors

Karan Kohli, Venu G. Pillarisetty, Teresa S. Kim

Summary: Immune cell infiltration into solid tumors and their interactions with chemokine receptors play a crucial role in tumor growth and the balance between effector and immunosuppressive cells. This review discusses the implications of dysregulated chemokine signaling in the tumor microenvironment and the potential for targeting chemokine signaling in cancer immunotherapy.

CANCER GENE THERAPY (2022)

Review Dermatology

Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma

Miranda C. Lahman, Kelly G. Paulson, Paul T. Nghiem, Aude G. Chapuis

Summary: Merkel cell carcinoma is a rare skin malignancy that demonstrates responsiveness to anti-PD(L)1 therapy in patients associated with Merkel cell polyomavirus or chronic UV exposure. Despite the low mutational burden in virus-positive MCC, the quality of antigens determines immunotherapy responsiveness, highlighting the potential effectiveness of cell-based therapies. Additionally, diverse T-cell infiltration patterns in VP-MCC suggest microenvironment plasticity and multifactorial contributions to immune recognition, with VP-MCC serving as an example of how antitumor adaptive immunity can provide biomarkers for early detection and monitoring of the disease.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Article Oncology

CD4+T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes

Brett A. Schroeder, Natalie A. LaFranzo, Bonnie J. LaFleur, Rachel M. Gittelman, Marissa Vignali, Shihong Zhang, Kevin C. Flanagan, Julie Rytlewski, Laura Riolobos, Brian C. Schulte, Teresa S. Kim, Eleanor Chen, Kimberly S. Smythe, Michael J. Wagner, Jose G. Mantilla, Jean S. Campbell, Robert H. Pierce, Robin L. Jones, Lee D. Cranmer, Seth M. Pollack

Summary: In dedifferentiated liposarcoma (DDLPS), high TCR clonality combined with low T-cell fraction predicts worse outcomes, while CD4+ T-cell infiltration is associated with better outcomes; CD14+ monocytes and M2 macrophages are associated with worse outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Peter H. Goff, Laura Riolobos, Bonnie J. LaFleur, Matthew B. Spraker, Y. David Seo, Kimberly S. Smythe, Jean S. Campbell, Robert H. Pierce, Yuzheng Zhang, Qianchuan He, Edward Y. Kim, Stephanie K. Schaub, Gabrielle M. Kane, Jose G. Mantilla, Eleanor Y. Chen, Robert Ricciotti, Matthew J. Thompson, Lee D. Cranmer, Michael J. Wagner, Elizabeth T. Loggers, Robin L. Jones, Erin Murphy, Wendy M. Blumenschein, Terrill K. McClanahan, Jon Earls, Kevin C. Flanagan, Natalie A. LaFranzo, Teresa S. Kim, Seth M. Pollack

Summary: This study aims to characterize the changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy and provides insights for neoadjuvant immunotherapy trial design. The results show that neoadjuvant therapy significantly increases immune cell infiltration in the tumor and affects the expression of immune-related genes and cytokines. These findings inform the incorporation of immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

CLINICAL CANCER RESEARCH (2022)

Article Orthopedics

Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis

Lee D. Cranmer, Bonny Chau, Jose G. Mantilla, Elizabeth T. Loggers, Seth M. Pollack, Teresa S. Kim, Edward Y. Kim, Gabrielle M. Kane, Matthew J. Thompson, Jared L. Harwood, Michael J. Wagner

Summary: This study examined the association between perioperative chemotherapy and overall survival in patients with dedifferentiated chondrosarcoma. The results showed that there was no significant improvement in overall survival associated with chemotherapy treatment.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2022)

Article Cell Biology

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency

Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson, Nathalie Vigneron, Denise Buenrostro, Felecia D. Wagener, Valentin Voillet, Lauren Martin, Raphael Gottardo, Jason Bielas, Julie M. McElrath, Derek L. Stirewalt, Era L. Pogosova-Agadjanyan, Cecilia C. Yeung, Robert H. Pierce, Daniel N. Egan, Merav Bar, Paul C. Hendrie, Sinead Kinsella, Aesha Vakil, Jonah Butler, Mary Chaffee, Jonathan Linton, Megan S. McAfee, Daniel S. Hunter, Marie Bleakley, Anthony Rongvaux, Benoit J. Van den Eynde, Aude G. Chapuis, Philip D. Greenberg

Summary: Understanding the mechanisms underlying tumor control or resistance is crucial for designing effective antileukemic immunotherapy. This study identified an immune escape mechanism in an AML patient and found that targeting epitopes generated by immunoproteasome-deficient cells can effectively control AML growth, potentially improving therapeutic efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Oncology

Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function

Joshua R. Veatch, Sylvia M. Lee, Carolyn Shasha, Naina Singhi, Julia L. Szeto, Ata S. Moshiri, Teresa S. Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S. Tykodi, Evan T. Hall, David R. Byrd, John A. Thompson, Venu G. Pillarisetty, Thomas Duhen, A. McGarry Houghton, Evan Newell, Raphael Gottardo, Stanley R. Riddell

Summary: This study utilized single-cell RNA sequencing to investigate tumor-specific CD4(+) T cells infiltrating human melanoma and identified their phenotypes and functions. The expression of these tumor-specific CD4(+) T cells in the tumor microenvironment correlated with the transcriptional states of CD8(+) T cells and macrophages, maturation of B cells, and patient survival.

CANCER CELL (2022)

Article Dermatology

Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis

Aubriana M. McEvoy, Kristina Lachance, Daniel S. Hippe, Kelsey Cahill, Yasman Moshiri, Christopher W. Lewis, Neha Singh, Song Y. Park, Zoe Thuesmunn, Maclean M. Cook, Nora A. Alexander, Lauren Zawacki, Hannah Thomas, Kelly G. Paulson, Paul Nghiem

Summary: This study aimed to estimate the risk of stage-specific MCC recurrence and mortality since diagnosis. The study included 618 MCC patients enrolled in a Seattle-based data repository from 2003 to 2019. The results showed a 5-year recurrence rate of 40% for MCC, with 95% of recurrences occurring within the first 3 years.

JAMA DERMATOLOGY (2022)

Article Biotechnology & Applied Microbiology

Production of an interleukin-10 blocking antibody by genetically engineered macrophages increases cancer cell death in human gastrointestinal tumor slice cultures

Kevin P. Labadie, Shannon A. Kreuser, Katherine J. Brempelis, Sara K. Daniel, Xiuyun Jiang, Kevin M. Sullivan, Alan F. Utria, Heidi L. Kenerson, Teresa S. Kim, Courtney A. Crane, Venu G. Pillarisetty

Summary: Although IL-10 can promote effector T-cell function, its overall effect in the tumor microenvironment appears to be suppressive. Thus, blocking IL-10 has therapeutic potential for enhancing antitumor immune function. Using genetically engineered macrophages (GEMs) as delivery vehicles, researchers created IL-10-blocking antibodies and demonstrated their efficacy in tumor models. The GEMs produced sustained levels of the antibody and led to a significantly higher rate of tumor cell apoptosis.

CANCER GENE THERAPY (2023)

Article Oncology

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Kristin G. Anderson, David A. Braun, Aitziber Buque, Sarah B. Gitto, Jennifer L. Guerriero, Brendan Horton, Bridget P. Keenan, Teresa S. Kim, Abigail Overacre-Delgoffe, Marco Ruella, Todd A. Triplett, Omkara Veeranki, Vivek Verma, Fan Zhang

Summary: Anticancer immunotherapies have shown improved outcomes in patients with various malignancies, but many patients do not respond or have durable responses due to immune resistance mechanisms. These mechanisms vary among patients with the same cancer type and involve multiple cell types. Advanced tumor profiling technologies can define immune resistance pathways, which can be used to categorize cancers into immune resistance archetypes. Targeted therapies addressing multiple cell axes and suppressive mechanisms based on these archetypes may improve efficacy and outcomes for individual patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Meeting Abstract Dermatology

The CDK4/6 inhibitor palbociclib enhances the vulnerability of Merkel cell carcinoma via the HIF2α pathway

J. Lee, A. Colunga, J. Lee, T. Pulliam, K. Paulson, V. Voillet, A. Berndt, C. Church, K. Lachance, S. Park, N. Yamamoto, M. Cook, M. Kawasumi, P. Nghiem

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

No Data Available